Lexatumumab tolerated for pediatric solid tumors
(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric ...
Oct 16, 2012
0
0